Skip to main content
Navigate Up
Sign In
 

Scleroderma & Systemic Sclerosis Trials


​The Division of Rheumatology strives to understand more about scleroderma and systemic sclerosis through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

​Study Name ​Brief Description Basic Eligibility Criteria​ ​Contact
Scleroderma Lung Study III (SLS III)​
COMIRB#: 17-1226
​The purpose of the study is
to research a new treatment
for Scleroderma related lung
disease (ILD). ​
​To qualify for study participation, you must be:
  • ​Over 18 years old
  • Diagnosed with Scleroderma (SSc) with in the last 7 years
  • Diagnosed with Interstitial Lung Disease (ILD)
  • No smoking in the last 6 months
  • Not pregnant or breastfeeding
​PI: Aryeh Fischer, MD

Study Coordinator: 
Mallary Crow Adams
303-724-8403

​Systemic Sclerosis (JBT-101)
WIRB 20172531
#16832316.0
​The purpose of the study is to research
Lenabasum (JBT-101), an experimental
drug that may reduce inflammation and
stop the development of scar tissue, also called fibrosis, which results from chronic active inflammation.

​​To qualify for study participation, you must be:
  • Diagnosed with diffuse cutaneous systemic Sclerosis
  • Must be 18 or older
  • Disease duration of 6 years or less
​PI: Aryeh Fischer, MD

Study Coordinator: 
Mallary Crow Adams
303-724-8403​
 
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.​